ABIRATERONE ACETATE- abiraterone acetate tablet Major Pharmaceuticals

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE
TABLETS.

ABIRATERONE ACETATE tablets, for o Initial U.S. Approval: 2011	ral use
REG	ENT MAIOR CHANGES
Warnings and Precautions (5.1)	05/2019
Warnings and Precautions (5.4)	05/2019
Warnings and Precautions (5.5)	05/2019
	ICATIONS AND USAGE
Abiraterone acetate tablets are a CYP17 in	hibitor indicated in combination with prednisone for the

we have store to be a CTP shallor included model of the sectors to the
 model of the sector starting of t

Date Modification: J. Storpaliers with baseline moderate legatic impairment (Chid-Fugh Class B), reduce the abiratero acotates starting done to 220 mg once dely, (2-4) J. For paliers the develop hypothosol dy during treatment, hol abiratenore acotate tablets until recovery. Retreatment may be initiated at a reduced date. Abiratenore acotate tablets should be discontinued gradients develop seven hypothosolicity (2-4)

discontinued if patients develop severe hepatotoocity: (2.4)

and Table 230 mg (3)

CONTRAINDICATIONS

Instant Birth 25 mg (1)
 CORRENT LINES
 (1)
 CORRENT
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (1)
 (

A regardless particular is an effective contrangence, (5, 1, 1, 2, 3)
 The second sec

Fight Cases (-), (0-0)
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 7/2020

- 12.1 Brothensing maximum
 12.1 Anamosohetis
 13.1 Garcingenetis, Malagnetis, Malagnetis
 13.1 Garcingenetis, Malagnetis, Malagnetis
 14.1 Garcingenetis, Malagnetis, Mala

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with

1. Metastatic castration-resistant prostate cancer (CRPC).

2 DOSAGE AND ADMINISTRATION

2 DOSAGE AND ADMINISTIA I UM 2.1 Recommended Dose for Metastatic CRPC The recommended dose of abilitatione acetate tablets is 1,000 mg (four 250 mg tablets) orally once daily with predinione 5 mg orally twice daily.

2.3 Important Administration Instructions

2.1 Insportent Administration Instructions
2.2 Instruct

Impairment (Cloich Fug), Clais C. Line of parallel and indexing Article support. Handbackskick For patients who develop inspationskich guiring tradiment with aborterons actuate tables (ALT and ork Argonaet than SULU), to table shall uppear than SULU), informing transmission of the aborterons and and tables (Line Weinhorgs and Practulators means of the functions to the babetist babetist of the Argonaetherons actuate tables (ALT and ork Argonaetherons SULU) and the Argonaetherons regard to 223 ULU) and total babetist of the Argonaetheron actuate the Argonaetherons and monthly handles of the Argonaetherons and argonaetherons and exclusion of the functionation and monthly handles of the Argonaetherons at enclosed loss of thom goin cade diploment that is the the Argonaetherons at enclosed loss of thom goin cade diploment that is the the function at enclosed loss of thom goin cade diploment that is the the function at enclosed loss of thom goin cade diploment that is the the function at enclosed loss of thom goin cade diploment that is the the function at enclosed loss of thom goin cade diploment that is the the function at enclosed loss of thom goin cade diploment that is the the function at enclosed loss of thom goin cade diploment that is the the function at enclosed loss of the Argonaetheron and the attracture that is the handless of the DAS ULU.

If hepatotoxicity recurs at the reduced dose of 500 mg once daily, discontinue treatment with abiraterone acetate tablets.

scattas tobate.
Permovanity discontinue abritationo as catatas for patients who develop a concurrent elevation of ALT greater than 3 x UUX in the interpretation of the scattas and the scattas and

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Hypokalemia, Fluid Retention, and Cardiovascular Adverse Reactions due to Mineralocorticoid Excess

Abriatrona scratale may cause hypertension, hypolatenia, and dar teterition as a consequence of increased mineralecorticols levels results CPUT hibbios (new partnersion, hypolatenia, and the teterition as a consequence of increased mineralecorticols levels results Control hypertension and correct hypolatenia before and during treatment with abriaterione actitute.

mia or fluid retention, such

jabraharone sectata. The stafey of abraharone sectate in patients with left ventricular ejection fraction <50% or New York Heart Association (NPAH) Class III or // Neart failure (in COU-AA. 201) or NPHA Class II to // Neart failure (in COU-AA 202) han on the em stabilished because these patients were excluded from these randomized clinical trials [see Clinical Studies [14]].

5.2 Advance-cartical Insufficiency and the second secon

ths of trea

nthly thereafter. If elevations in ALT and/or AST greater than 5X upper limit of normal (ULN) or total bilirubin greater than 3X ULN occur in patients with base

3 DOSAGE FORMS AND STRENGTHS Abiraterone acetate 250 mg tablets, USP are white to off-white, oval, biconvex uncoated tablets. Engraved "A250" on one side, "APO" on the other side.

In postmarketing experience, there have been abiraterone acetate-associated severe hepatic toxicity, including fulminant hepatits, acute liver falure and deaths [see Adverse Reactions (6.2)].

near users (P. d/): In the combined data of randomized circical traits, grade 3 to 4 ALT or AST increases (at least 35 ULU) were reported in (% d 2326 patients who received abstratomo extata, by pack of any (at the 13 months) and to any one provide the source bable and the source of the beginning with normal values. Transmers discontinuation due to ALT and AST increases or absormal happed: Interface on the source of the source

reported take is hapitatorsky event. It is taken us and us to a chart were based on a second second

Containing the Cooking of the Containing of the Containing of the Cooking of t

Administration (2-3):. Permanently discontinue abiraterone acetate tablets for patients who develop a concurrent elevation of ALT greater than 3 x ULN and total bilinubin greater than 2 x ULN in the absence of bilary obstruction or other causes responsible for the concurrent elevation (see Dosage and Administration (2-4)).

The safety of abiraterone acetate re-treatment of patients who develop AST or ALT greater than or equal to 20X ULN and/or bilirubin greater than or equal to 10X ULN is unknown. 5.4 Increased Fractures and Mortality in Combination with Radium Ra 223 Dichloride

Dichoide Dichoide the plus predinisone/predinisolene is not recommended for use in combanison with redum 223 dichordre outside of cincal traits. The cincia effices, and adary of concurrent histiation of abitaterone accitate plus predinsone/predinisolene and radium Re 223 dichordre was assessed in a radiomized, pacho-controller dinuctement radiu (RPA-227 truit) is diog planetic with asymptomatic profiles) symptomatic carb diolor seasant protable cancer with toore mediates. The recommendation. Use based on an independent blank behaviore Gommittee recommendation.

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths 84.85% vs 35.5%) have been observed in patients who received abiraterone acetate plus predisione/predisione in combination with radium Ra 223 dichoride compared to batingt who received datacebo in combination with abiraterone acetate plus

5.5 Embryo-Fetal Toxicity

>> cm/portext Touckty Inside and the set of partners excited have not been established in finnales. Based on main reproductive subles and mechanism of action, abirdemone acate can also that balm and as too is dipagainary with an adiationation of a paragometic harring organogenesis caused above and excited that a paragometic harring organogenesis caused above and excited that an atomical exposures paragometical acate and above and acate and a set of the adiation of a set is and advection of the advection of the advection of a set of a set is a distance of a set of the advection of the advection of a set of a set of advections or advection of the advection of a set of a set is a distance of advection of the advection of a set of a set of a set of advections or advection of the advection of a set of the advection of the odvection of the advection of the advecti

6 ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling

Hypotalamia, Full Retention, and Cardiovascular Adverse Rectantis due to Monadocritical Excess (see Warnings and Precutations (E.J.)). Hypotalamia, Full Retention, and Cardiovascular Adverse Rectantis due to Monadocritical Excess (see Warnings and Precutations (E.J.)). Honotexet (See Warnings and Precutations (E.J.)). Honotexet Precutations and Netholation with Rodum Ra 223 Dicheride Icer Warnings and Precutations (E.J.). S. Chicka Trial Experience Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Manamatoria and the Second Restauro Frige Trials are required in the Second

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Recard the drag are conducted under weder warming conductors, alwares networks of the drag are most of the drag are most of the the trans conductors. Alwares networks the drag are drag are most of the the trans conductors are drag are the drag are the drag are are drag are are drag are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are are drag are drag are drag are drag are are drag are drag are drag are drag are are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are are drag are drag are drag are drag are are drag are drag are drag are drag are are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are are drag are drag are drag are drag are drag are more are drag are drag are are drag are are drag are are drag are are drag are are drag are are drag are

COLFAA-301 encoded 1195 patients with metastatic CRPC who had received prior docetaxel chemotherapy. Patients were not eligible if AST and/or ALT ≥2.5X ULN in the absence of liver metastases. Patients with liver metastases were excluded if AST and/or ALT >5X ULN.

Table 1 shows adverse reactions on the abiraterone acetate arm in COU-AA-301 that cocurred with a 27% absolute increase in frequency compared to placebo or were events of special interest. The median duration of treatment with abiraterone acetate with predictione was 8 months.

Table 1: Adverse Reactions due to Abiraterone Acetate in COU-AA-301 Abiraterone Acetate with Prednisone Prednis Adverse reaction Musculoskeletal and connective tissue disorders oht sweling/discomfort Muscle discomfort³ 30 scle discomfort³ neral disorders cular disorders 17 5 9 t flush pertension strointestinal orders rrhea pepsia ections and estations hary tract infection ction miratory, thoracic

nd mediastinal lisorders					
lough	11	0	7.6	0	
tenal and urinary lisorders					
Irinary frequency	7.2	0.3	5.1	0.3	
locturia	6.2	0	4.1	0	
njury, poisoning and rocedural omplications					
ractures ⁵	5.9	1.4	2.3	0	
ardiac disorders					
rrhythmia ⁶	72	11	4.6	1.0	

Irinary frequency	7.2	0.3	5.1	0.3
locturia	6.2	D	4.1	0
njury, polsoning and rocedural omplications				
ractures ⁵	5.9	1.4	2.3	0
ardiac disorders				
rrhythmia ⁶	7.2	1.1	4.6	1.0
hest pain or chest liscomfort ⁷	3.8	0.5	2.8	0
Cardiac failure ⁸	2.3	1.9	1.0	0.3

 Table 2: Laboratory Altommalities of Interests

 0:004.43.031
 Marchartorson
 Reache with Accetate with Precisionen

 Aboratory Classical Control
 Marchartorson
 Reache with Accetate with Accetate with Accetate with Alton State Precisionen

 Aboratory Classical Control
 Marchartorson
 Reache with Accetate with Accetate with Alton Precisionen
 National Altonal Altonal Accetate with Altonal Accetate with Altonal Accetate with Altonal Accetate with Altonal Accetate A

erse reaction eral disorders que

⁶Includes terms Arrhythmia, Tachycardia, Atrial fibrillation, Supraventricular tachycardia, Atrial tachycardia, Ventricular tachycardia, Atrial flutter, Bradycardia, Atrioventricular block complete, Conduction disorder, and Bradyarrhythmia. ⁷Includes terms Angina pectoris, Chest pain, and Angina unstable. Myocardial infarction or ischemia occurred more commonly in the placebo arm than in the abiraterone acetate arm (1.3% vs. 1.1% respectively). ⁶Includes terms Cardiac failure, Cardiac failure congestive, Left ventricular dysfunction Cardiagenic shock, Cardiamegaly, Cardiamyapathy, and Ejection fraction decreased. Table 2 shows laboratory abnormalities of interest from COU-AA-301 Table 2: Laboratory Abnormalities of Interest In COU-AA-301

COU-AA-302: Metastatic CRPC Prior to Chemotherapy COU-AA-302 enroled 1088 palents: with metastatic CRPC who had not received prior cytotoxic chemotherapy. Patients were ineligible FA3 standard AT x2.5X UIN and palents were excluded if they had liver metastates. Table 3 shows adverse reactions on the adverseme accette arm in COU-AA-302 that Table 3 shows adverse reactions on the abitatrone acetate arm in COU-AA-302 that occurred n 2% of patients with a 2% absolute increase in frequency compared to placebo. The median duration of treatment with abitaterone acetate with predinisone was 13.8 months.

128 million. Table 31. Adverse Reactions in 25% of Patients on the Abiraterone Acetate Amin COU-AA-302 Abiraterone Acetate with Placebo with Predisione Predisione Nu-5421 Septembolic and Charles Placebo Adverse State Predisione State State State Predisione

39 2.2 34 1.7 25 0.4 21 1.1

³Includes terms Muscle spasms, Musculoskeletal pain, Myagia, Musculoskeletal disconfort, and Musculoskeletal stiffness. "Includes terms Edema, Edema peripheral, Ptting edema, and Generalized edema. ⁵Includes all fractures with the exception of pathological fracture.

Eardiac tationer ¹Adverse events graded according to CTCAE version 3.0. ²Includes terms Arthritis, Arthraigia, Joint sweling, and Joint stiffness. ³Control of the second statement of the se

Pyrexia	8.7	0.6	5.9	0.2
Musculoskeletal and	onnective	e tissue disord	iers	
oint swelling/discomfort	3 30	2.0	25	2.0
Groin pain	6.6	0.4	4.1	0.7
Gastrointestinal disor	ders			
Constipation	23	0.4	19	0.6
Diarrhea	22	0.9	18	0.9
Dyspepsia	11	0.0	5.0	0.2
Vascular disorders				
Hot flush	22	0.2	18	0.0
Hypertension	22	3.9	13	3.0
Respiratory, thoracic	and medi	astinal disorde	irs	
Cough	17	0.0	14	0.2
Dyspnea	12	2.4	9.6	0.9
Psychiatric disorders				
Insomnia	14	0.2	11	0.0
Injury, polsoning and	procedura	al complication	s	
Contusion	13	0.0	9.1	0.0
Fals	5.9	0.0	3.3	0.0
Infections and infesta	tions			
Upper respiratory tract	13	0.0	8.0	0.0
Nasopharyngitis	11	0.0	8.1	0.0
Renal and urinary disc	orders			
Hematuria	10	1.3	5.6	0.6
Skin and subcutaneou	is tissue (disorders		
Bash	8.1	0.0	3.7	0.0

¹Adverse events graded according to CTCAE version 3.0. ²Includes terms Edema peripheral, Pitting edema, and Generalized edema ³Includes terms Arthritis, Arthraigia, Joint swelling, and Joint stiffness.

Table 4 shows laboratory abnormalities that occurred in greater than 15% of patients, and more frequently (>5%) in the abiraterone acetate arm compared to placebo in COU-AA-302.

Table 4: Laboratory Abnormalities in >15% of Patients in the Abirate

Acetate Arm of COU-	AA-302				
	Abiraterone Prednisone (N=542)	Acetate with	Placebo with Prednisone (N=540)		
Laboratory Abnormality	Grade 1-4%	Grade 3-4%	Grade 1-4%	Grade 3-4%	
Hematology					
Lymphopenia	38	8.7	32	7.4	
Chemistry					
Hyperglycemia ¹	57	6.5	51	5.2	
High ALT	42	6.1	29	0.7	
High AST	37	3.1	29	1.1	
Hypernatremia	33	0.4	25	0.2	
Hypokalemia	17	2.8	10	1.7	

Hypokalemia ¹Based on non-fasting blood draws.

Cardiovascular Adverse Reactions

In the constrained and or mandminical phonon-bound with a statistic statisti statistic statisti statistic statistic statistic

placebo group. In the same combined data, the majority of arrhythmise were grade 1 or 2. There was one death associated with arrhythmise and three patients with sudden death in the advanceroe accelerate arms and file deaths in the placebo arms. There were 7 (0.3%) deaths in due to cardiorespriatory arrest in the abviatrome. Acceltar arms and 2 (1.0%) deaths in the placebo arms. Any cardinal lachemia or myocardial infrarction led to death in 3 patients in the placebo arms and 3 deaths in the advancemo acceltar arms.

6.2 Postmarketing Experience

6.2 Performantation Experience
16.3 Performantation Experience
16.4 Description and an experimentation of the sense identified during parts approval approvan

7 DRUG INTERACTIONS

7 ONU INTERACTIONS 21 Darget that Inheles I radius: CYP3A4 Enzymes Based on in vito data, abritationes exclute its a subsittate of (PSIA4. In a solicitate) data y particular to a strong (PSIA4 indicates) data particular to a strong (PSIA4 indicates) data particular to a strong international indicates data particular its a strong (PSIA4 indicates) data particular to a strong international indicates data particular its a strong (PSIA4 indicates) data particular to a strong international indicates data particular its a strong (PSIA4 indicates) data particular to a strong international indicates data particular to a strong international indicates data particular to a strong indicate data particular to a strong international indicates data particular to a strong international indicates data particular to a strong indicate data particular to a strong indicates data parting indicates data particular to a strong indicates data particular In a dedicated drug interaction trial, co-administration of ketoconazole, a strong inhibit of CYP3A4, han o clinically meaningful effect on the pharmacokinetics of abiraterone (see Clinical Pharmacology (12.3)).

The Christ Potennice Sty (12.3). **3.2** Effects of Montennean a Drug Michaloking Exyment Abriatmen extents is an in-biblior of the Inputs' drug in-attoching maynes: CVP206 detorsmitteness and the start of the Inputs' drug in-attoching maynes: CVP206 detorsmitteness and the Inputs' drug in a start of 16 drug regulations of CVP206. In a cVP206 substantial were increased 3.8 and 2.9 fold; regulations in a CVP206 in a cVP206 substantial were increased 3.8 and 2.9 fold; regulations in a CVP206 and CVP206 substantial were increased 3.8 and 2.9 fold; regulations in a CVP206 and CVP206 substantial were increased 3.8 and 2.9 fold; regulations in a CVP206 and CVP206 substantial on the Input substantianed of the Interness and CVP206 substantiane drug (see CVP206 and Input substantianed of the Interness and CVP206 detorsmitteness and the Internet Start Start Start Bergelates one is growed and the Internet Start Bergelates one is

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy Risk Summary

The safety and efficacy of abiraterone acetate have not been established in females. Based on findings from animal studies and the mechanism of action, abiraterone acetate can cause fetal harm and potential loss of pregnancy.

Curr current can mann and potential case or physicine 2. There are no human data on the use of abiraterone acetate in pregnant women. In animal reproduction studies, oral administration of abiraterone acetate to pregnant rats during organopenesis caused adverse development effects at matternal exposures approximately ≥ 0.03 times the human exposure (AUC) at the recommended dose (see Data).

Data Animal Data

Annual Data In a methop-shall developmental toxicity study in rais, abratesime acctate caused in a methop-shall be and the study in rais, abratesime acctate caused throughout the period of organogenesis (gestational days (s 6 ± 1)). Findings include interplo feal shall be provided in the study of the study in the study of the study of the study in the study of the study of the study of the study of the distance at 2 milliographic and decreased the dow weight at 100 milliographics. The advectment of the study of the study of the study of the study of the exposure (AlcC) approximately 0.02, 0.1 and 0.3 times, respectively, the ALC in patients.

acquires (AUC) approximately 6.01, 6.1 and 0.3 time, respectively, the AUC is particle. **3.2 Lattice 3.3 Lattice 3.3 Lattice 3.4 Lattice 3.4 Lattice 3.5 Lattice 3.5 Lattice 3.6 Lattice 3.6**

Based on animal studies, abiraterone acetate may impair reproductive function and fertility in males of reproductive potential [see Nonclinical Toxicology (13.1)].

8.4 Pediatric Use Safety and effectiveness of abiraterone acetate in pediatric patients have not been established.

8.5 Geriatric Use

2.3 strains, see 2.3 bits bala units of paleties multilyg abstratore scatter in reactorney clicks tables, 0.1 the bala units of the strain and evan and 71 the entry 1 pars and one. It has oursal differences in safety or effectiveness, were observed between these eletity patients and younger patients. Other reports clicks approximate hours and the effective response between the eletity and younger patients, but greater sensibility of some differ individual cannot be ruled out.

8.6 Patients with Hepatic Impairment

b.6 Fabrics with Repair: Impairment The frammaceland in the state of the state or motioned in Medi Teppice Impairment (CIAP-Papir) Class A and B, respectively and in a finality control state state in normal Repair functions. The systemic exposure (AUC) approximation, 12 field and 3.6 folds in subjects with million and moderate baseline height in systematic state of the state of the state state of the state of the state approximation. The state of the state of the state of the state of the state approximation of the state approximation of the state baseline state of the state baseline state of the state state of the state state of the state state of the stat

hepatic function. In the second secon

(12.3)). For patients who develop hepatotoxicity during treatment, interruption of treatment and dosage adjustment may be required (see Dosage and Administration (2.4), Warnings and Precautions (5.3), and Clinical Pharmacology (12.3)).

8.7 Patients with Renal Impairment No dosage adjustment is necessary for patients with renal impairment [see Clinical Pharmacology (12.3)].

10 OVERDOSAGE Human experience of overdose with abiraterone acetate is limited. There is no specific antidote. In the event of an overdose, stop abiraterone acetate, undertake general supportive measures, including monitoring for arrhythmias and cardiac failure and assess liver function.

11 DESCRIPTION

11 DESCRIPTION Abritatrone acctate, USP the active ingredient of abiraterone acctate tablets, USP is the acetyl cetter of abiraterone. Abiraterone is an inhibitor of CPE17 (17a-hydrox/ussic172-05/ase). Each abiraterone acctate acids: USP container 250 mg of abiraterone acctate. USP. Abiraterone acctate acids: USP is designated chemically as (38)-17. Spyridinyl androxa 5, 16- den-3, 49. acctate and its structure is:

Abiraterone acetate, USP is a while to off white, non-hygroscopic, crystalline powder. I molecular tormula is C₂ylt₂H0₂ and it has a molecular weight of 391.55 g/mol. Abiraterone acetack. USP is a logofiltic compound with an octand-water partition coefficient of 5.12 (Log P) and is practically insoluble in water. The pKa of the aromatic nifrogen is 5.19.

Abiraterone acetate tablets are available in 250 mg uncoated tablets with the following inactive ingredients: coloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, and sodium lauryl sulfate. 12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Abixeterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis.

converses. CPT1 calayees two sequential reactions: 1) the conversion of pregnenoione and progesterone to their 17a-in-firstory derivatives by 10-in-forcing/sea activity and 2) the subsequent formation of derivary/capanicatorene (DIREA) and and/orstenedione, respectively, by C17, 20 yase activity. DREA and and/orstenedione are androgens and an precursors of testsforme. Inhibben of CPT19 by abstratence can be result in increased interactivity. Inter CPT19 by abstratence can be result in increased interactivity production by the adversal. [Sau]

The second secon

adaption the addition of the second s

Line and the set of the set of

Affer of oppourse sets. CPFAA and SULTAA's or the margine involved in the formation of advancement of advanceme

Drug Interactions In vitro studies with human hepatic microsomes showed that abiraterone has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.

and CTPMAS. In an invision of the product of the Course and AUC of destrumentary types of the product of the p

In a separate clinical pharmacokinetic interaction study of healthy subjects, co-administration of kotoconazole, a strong inhibitor of CVP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone (see Drug Interactions (7.1)).

In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of piogltazone was increased by 46% when piogltazone was given together with a single dose of 1,000 mg abiraterone acetate (see Drug Interactions (7.2)). In vitro, abiraterone and its major metabolites were shown to inhibit the hepatic uptake transporter OATP1B1. There are no clinical data available to confirm transporter based interaction.

13 NONCLINICAL TOXICOLOGY

13 HORCURLECK TOXICOLOGY
13 LGC ACCOUNT AND ADDRESS TO ADDRESS ADDRES nas in the testes at all dose levels tes


ted This fire


tive system were observed at ≥50

monkeys de opposures approximately 6.6 times the AUC in Numari. In 3 high any han the rest is related tops weights of the perspective system, sperm counts, sperm modely, altered sperm monphology and discresses of entity were desaved in mana. Actors for a rest as 21 mg/slights and ARterg of writering formale and in a factor of a rest as 21 mg/slights and ARterg of writering formale and of corpora table, repetations and the embryses and an increase in Actors of a rest of a rest and any spectra and any spectra and any spectra and any spectra discretions and any spectra and any spectra and any spectra and any spectra perspectra basis, repetations and the state of the spectra and any spectra perspectra basis. The spectra and any spectra and any spectra and any spectra perspectra basis. The spectra and any spectra and any spectra and any spectra perspectra and any spectra perspectra and any spectra perspectra and any spectra any spectra and any spectra any spectra and any spectra and

13.2 Animal Toxicology and/or Pharmacology

A dose-dependent increase in cataracts was observed in rats after daily oral abiraterone acetate administration for 26 weeks starting at ≥50








NR=Not reached. ¹ p-value is derived from a log-rank test stratified by ECOG performance status score (0 vs. 1). vs. 1). ² Hazard Ratio is derived from a stratified proportional hazards model. Hazard ratio <1 favors abinaterone acetate with predinktone. Figure 3: Kaplan Meier Curves of Radiographic Progression-free Survival In COUAA-302 (Intent-to-Treat Analysis)






¹ p-value is derived from a log-rank test stratified by ECOG performance status score (0 vs. 1). ² Hazard Ratio is derived from a stratified proportional hazards model. Hazard ratio <1 travors abiraterone acetate with prednicone.
Figure 2: Kaplan Meler Overall Survival Curves in COU-AA-302

may prolong OS in metastatic CRPC. therapy in 13% of patients on the at placebo arm. Table 8: Overall Survival of Patk or Placebo in Combination with Analysis)	eraterone acetate arm and	used as a subsequent 44% of patients on the r Abiraterone Acetate
Overall Survival	Abiraterone Acetate with Prednisone (N=546)	Placebo with Prednisone (N=542)
Deaths	354 (65%)	387 (71%)
Deaths Median survival (months) (95% CI) p-value ¹	354 (65%)	387 (71%)

months) demonstrated a stal abiraterone acetate with prec prednisone (Table 8 and Figu acetate arm and 78% of patis may prolong OS in metastatic	OS, conducted after 741 deaths (median follow up of 49 stically significant OS improvement in patients treated with inisone compared to those treated with placebo with re 2). Skty-five percent of patients on the abiraterone nots on the placebo arm used subsequent therapies that CRPC. Abiraterone acetate was used as a subsequent the abiraterone acetate arm and 44% of patients on the
	f Patients Treated with Either Abiraterone Acetat with Prednisone in COU-AA-302 (Intent-to-Treat

vith

Concerning and the second seco



² Hazard Ratio is derived from a stratified prop favors abiraterone acetate with prednisone. ards model. Hazard ratio <1 Figure 1: Kaplan-Meler Overall Survival Curves in COU-AA-301 (Intent-to-Treat Analysis)

¹ p-value is derived from a log-rank test stratified by ECOG performance status score (0-1 vs. 2), pain score (absent vs. present), number of prior chemotherapy regimens (1 vs. 2), and type of disease progression (PSA only vs. radiographic).

	Abiraterone Acetate with Prednisone (N=797)	Placebo with Prednisone (N=398)
Primary Survival Analysis		
Deaths (%)	333 (42%)	219 (55%)
Median survival (months) (95% CI)	14.8 (14.1, 15.4)	10.9 (10.2, 12.0)
p-value ¹	<0.0001	
Hazard ratio (95% CI) ²	0.646 (0.543, 0.768)	
Updated Survival Analysis		
Deaths (%)	501 (63%)	274 (69%)
Median survival (months) (95% CI)	15.8 (14.8, 17.0)	11.2 (10.4, 13.1)
Harrard ratio (05% CI)2	0 740 (0 629 0 950)	

Table 7: Overall Survival of Patients Treated with Either Abiraterone Acetate or Placebo in Combination with Prednisone in COU-AA-301 (Intent-to-Treat

The entropy of the second process of the second sec

or click of proprints in high results are means a way, and a program size and a problem in the following paties the mean set of the set of the

COU-AA-301: Patients with metastatic CRPC who had received prior docetaxel chemotherapy doctasel chemotherapy in COLA-301 (CH0038890), a total of 1159 galants were renderinded 21 to totelable in COLA-301 (CH0038890), a total of 1159 galants over renderinden web predistores trig orally twice day (N=707) or placted once day place predistores that and y twice day (N=301). If plants readomined to sharp are were to continue institution and y twice day (N=1001). If plants readomined to sharp are were to continue institution and y twice day (N=1001). If plants readomined to sharp are were to continue institution and y twice day (N=1001). If plants readomined to sharp are were to continue institution baselinemain together with protocol defined radiographic progression and symptomatic or clical progression, initiation of new readment, uncaceptable backy) or which walk

The efficacy of a safety of absolutering actual with professione was the efficacy and actual of absolute constant international structures. All patients in these studies received a Griff analog or had prior balarcia orchictome, Patients with prior keckconarole treatment for orchictome, actual structures are excluded from these trias. Concurrent use of spronobscione was not absolved during the study period.

14 CLINICAL STUDIES

mg/kg/day (similar to the human clinical exposure based on AUC). In a 39-week monkey study with daily oral abiraterone acetate administration, no cataracts were observed at higher doses (2 times greater than the clinical exposure based on AUC).

16 HOW SUPPLIED/STORAGE AND HANDLING

A storage of Leader 2013 and Leader 2013 are write to off white, and biomness uncoded biometry and the storage of the storage

Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

ee r j see uor se Loniouein noom inmiseraurus, Keep uor fi reach of haldren. Based on is mechanism of action, abiratarone acetate may harm a developing fetur Women where are groupding of women kin may be preguart shows nook bartak Women where are groupding of women kin may be preguart shows nook bartak Women where are program of the shows and the providence (31).

17 PATIENT COUNSELING INFORMATION
Advise the platters to read the FDA-approved patient liability gratees information)
 Hookenets. Takis Retretion, and Cardiovance Adverse Resolutions
 Honor platters that the directions contain a secondaria with hypothesison.
 hypothesims, and perspheral ideases that may load to G presexplation and Transid honor platters to a secondaria with hypothesison.
 hypothesims, and perspheral ideases that may load to G presexplation and Transid platters to characterize advectaria.
 Honor platters to a contracterized as a lease contained with hypothesison.
 Hopedeedings
 platters to characterize advectaria advectariang advectaria.
 (2.1)
 (2.1)

ocortical Insufficiency

Anticontent insurances, Inform patient has balantenine accitate with predisione is associated with adrenal to the healthcare provider (see Warnings and Precautions (3.2)). Healthcare provider (see Warnings and Precautions (3.2)). Healthcare (See Warnings and Precautions (3.2)), Healthcare (See Warnings and Precautions (3.2)), Inform patients that here for inclusion is encontened using balances. Addres patients to immediately report syndromic of healthcare (5.2), provide (see Warning and Precautions (3.2)).

provide (see warnings and inclusion); 5-JJJ. Len Contribution Mit Maultin Ba22 (Schoolds) Advice patients that radium Ra 222 dictionide schoold an increase in mortality and an increase rate of inclusione. Inform patients to speak with their healthcare provider about any order medications of treatment their and are currently taking for prostate cance (see Warnings and Proceadors (S-A)).

Dating and Administration
Dating and Administration
Data and Administration
problem on the state address or state tables are taken once daily with
problemone fluxts daily according to their heathcare providers instructional
problemone address of the state address and tables are tables are
address of the state address of the state address of the state address
of the state address of the state address of the state address of the state address
of the state address of th

Embryo-Fetal Toxicity

Internal Entructure Linkom patients that advantamore actuate may harm a developing fetus and can success be program. Consists of program. Construction of the presenters of reproductive potential to use effective contraception during treatment and for 3 seeks after the find advantamo-actent tables, pine lise in Specific Program. Success and the presenter and for 3 seeks after the find advantamo-actent tables, pine lise in Specific Program. Construction of the presenter and for 3 seeks after the find advantamore actent tables, pine lise in Specific Program. Construction of the presenter and for 3 seeks and the presenter of the Interpret Programmers and a find the presenter and the presenter of the p

Infertility

Advise male patients that abiraterone acetate may impair fertility [see Use in Specific Populations (8.3)].

APOTEX INC. Abiraterone Acetate Tablets, USP 250 mg

Manufactured Manufactured by: for: Apotex Inc. Apotex Corp. Toronto, Ontario Weston, Florida Canada M9L 1T9 USA 33326 Distributed By: MAJOR® PHARMACEUTICALS

MAJOR® PHARMACEUTICALS 17177 N Laurel Park Dr., Suite 233 Livonia, MI 48152 Revised: July 2019 Rev: 9

PATIENT INFORMATION Abilitations Accelet Tablets, USP (a) bit of serio and a set total) What are Abilitationed Accelet affabers? Abilitationes accelet abilities are sinter crystein medicine that is used along with his spread to other parts of the body. Abilitationes accelet abilities are not for use more. It is not income if abitationes accelet abilities are different in them.

Before you take Abiraterone Acetate Tablets, tell your healthcare provider about all of your medical conditions. including if you:

Particle and point distant rate. Tell your healthcare provider about all the medicines you take or treatment you receive, including prescription and over the-counter medicines, vitamins, and herbid supplements. Abstratories accetatic can interact with many other medicines. You should not start or stop any medicine before you tak with the healthcare provider that prescribed abstratories tablets.

Know the medicines you take. Keep a list of them with you to show to your healthcare provider and pharmacist when you get a new medicine. How should I take Abiraterone Acetate Tablets?

ev should take Abstaterione Accelst Tablet? I has abstaterione accelsta tablets and professiones excits a your healthcare moder that you. The should be ablet to the should be ablets and the should be the should be ablets and the should be ablets and the tablets and tablets and tablets and profession tablets and tablets I have been ablets and tablets and employed be ablets and tablets I have been ablets and tablets and the should be ablets and tablets I have been ablets and tablets and the should be ablets and tablets I have been ablets and tablets and the should be ablets and tablets I have been ablets and tablets and the should be ablets and the should be provide the should be ablets and the should be ablets and the should be in the should be ablets and the should be ablets and the should be provide tablets and the should be ablets and

What are the possible side effects of Abiraterone Acetate Tablets? Abiraterone Acetate Tablets may cause serious side effects includin

reserves Activity is about they classic service are effect in recuency: high block pressure (hypertension), how block pressures may be appressive they are appressive to the service and they are appressive transmission of the service and the service and the service and with advances activity as your handler can provide table you have any appressive the service and the service and the service with advances activity as your handler can provide table you. How with advances activity as your handler can provide table you with advances activity and any appressive of the service and postsume heads, and excise the service and a supportiones of the service activity month during transment with advances activity to be following synthemics.

•• dizziness confusion

muscle weakness · fast or irregular heartbeats

•• feel faint or lightheaded pain in your legs

 headache swelling in your legs or feet

A deread problems may happen if you stop taking productions, get an infection, or are under stress. **J Leer problems**. You may develop changes in lever function blood text: hour heahtrace provider will do blood texts to check your here before treatment with abstraterone activate tablets: and winty retarement with abstraterone activate tables. Liver failure may accur, which can lead to death. Tel your heakthcare provider if you notice any of the blowing changes.

yellowing of the skin or eyes
 darkening of the urine
 severe nausea or vomiting

3. severe nauses or vomtrig Increased risk to floor fracture and death when abiraterone acetate tablets and predisione or predincione, is used in combination with a type of radiation caled radium Rad 2013 dichrider. Is your handhace any provider about any other treatments you are tabling for protatise came. The most common size. The most common size.

In most common see enteries of advancementa acteate enco electropy any trans electropy any trans electropy trans electropy any tran certain other abnormal blood tests

Abiraterone acetate tablets may cause fertility problems in makes, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of abiraterone acetate. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Abiraterone Acetate Tablets? 1. Store abiraterone acetate tablets at room temperature between 68°F to 77°F (20°C to 25°C).

Steme advancement excitate tabelts are room temperature between 64°F to 77°F C0°C to 25°C.
 To advancement excitate tabelts and all medicines out of the reach of the formation between the tabelts and an excitate tabelts.
 Stepe advancement excitate tabelts are controlled to the reach of the r

Manufactured Manufactured by: for: Apotex Inc. Apotex Corp. Toronto, Ontario Weston, Florida Canada M9L 1T9 USA 33326

Landa H9: 119 USA 33326 Distributed By: MAJOR® PHARMACEUTICALS 17177 N Laurel Park Dr., Suite 233 Livenia, MI 48152 Revisjuly 2019 Rev: 9

Package/Label Display Panel Abiraterone Acetate Tablets, USP 250 mg 30 Tablets



BIRATERO		TATE					
Product Infor	mation						
Product Type		HUMAN PRESCRIPTION DRUG	item Code (Source)	NDC:090 4327)	04-6948(M	x::60505-	
Route of Admin	istration	ORAL					
Active Ingred	ient/Activ	Molety					
		redient Name		Basis of S		floor other	
Abiraterone Acet		OCRVIJE) (Abiraterone - UNE	G819A456D0)	Abiraterone A		250 mg	
Inactive Ingre	dients						
		Ingredient Name			51	trength	
SILICON DIOXIDE							
		5%) (UNI: 68401960MK)					
Lactose Monohyd							
Magnesium Stear							
Sodium Lauryl Su	ifate (UNI: 3	(8GB5141))					
Product Char							
Froduct Chars		e to to off-white)	Score				
	OVAL (Bico			Size		no score	
Shape	OWL (MCG	14630	Size	4250 480			
Contains			imprint	Cone	ASU	040	
Contains							
Packaging							
# Item Code		ackage Description	Mark	eting Start Date		ting End late	
1 NDC:0904-6948-	30 in 1 CART	ON	11/22/2	119			
1	1 in 1 BLISTE Product	R PACK; Type 0: Not a Comb	ination				
Marketing	Informa	tion					
Marketing Category		ation Number or Monog Citation		keting Start Date	Marka	ating End Date	
ANDA	ANDA2084	62	11/23/	2018			
abeler - w	ior Pharmace	uticals (191427277)					
Registrant	 Apotex Inc 	. (209429182)					

Revised: 12/2021